Latanoprost Noridem

Latanoprost, the active ingredient in Latanoprost Noridem, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is used in the management of open‑angle glaucoma and ocular hypertension.

GNH USA supplies Latanoprost Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to treat conditions that involve elevated intraocular pressure.

Open-angle glaucoma: reduces intraocular pressure to slow disease progression. Ocular hypertension: lowers intraocular pressure to prevent conversion to glaucoma. Secondary open-angle glaucoma: may be used as adjunct therapy to achieve target pressure.

Latanoprost may cause ocular and peri‑ocular reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris color change: gradual darkening of the iris. - Eye irritation: burning or stinging sensation. - Blurred vision: transient after instillation. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis. - Allergic reaction: swelling, itching, or rash. - Paradoxical IOP increase: unexpected rise in pressure. - Corneal edema: swelling of the cornea. - Vision loss: sudden decrease in visual acuity. - Persistent ocular pain: requires medical evaluation.

Before using Latanoprost, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown excretion; use with caution. Contact lens wearers: may cause deposits; remove lenses before instillation. Active ocular infection: defer use until infection resolved. Monitor intraocular pressure: ensure therapeutic response and adjust therapy as needed. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: risk of excessive IOP lowering. - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Systemic carbonic anhydrase inhibitors: can alter IOP control.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may require monitoring. - Topical corticosteroids: may diminish Latanoprost effect. - Systemic antihistamines: possible reduced ocular absorption. - Other ocular hypotensive agents: monitor for synergistic pressure lowering.